Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

and development expenses for the year ended December 31, 2008 totaled $46.5 million compared with $38.9 million in 2007. Research and development expenses were $13.9 million for the three months ended December 31, 2008 compared to $9.3 million for the same quarter the previous year. The increase in expenses was the net result of: achieving full enrolment of clinical sites and patients in the MAESTRO-03 trial; increased costs for the MAESTRO-02 trial as patients enter the trial; reduced costs of the MAESTRO-01 and MINDSET-01 trials as more patients complete these trials; a decrease in drug manufacturing expenses as the manufacture of validation batches is completed; a licensing bonus payment related to the Agreement with Lilly, and; additional expenses related to alliance management and support.

At December 31, 2008, cash and cash equivalents and short-term investments totaled $90.4 million as compared to $37.9 million at December 31, 2007. At December 31, 2008, the Company had working capital of $81.3 million as compared to $32.8 million at December 31, 2007. Management estimates that the current working capital is sufficient for the Company to meet its obligations in respect of the currently initiated clinical trials.

As at December 31, 2008 there were 91,009,323 Class "A" common shares of the Company issued and outstanding.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchan
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... MI (PRWEB) November 22, 2014 ... to simulate the proper management of life-like respiratory ... test lung devices . Grand Rapids-based, Michigan Instruments ... to donate two of the respiratory simulation units ... $15,000 each. Grand Valley and Muskegon Community College ...
(Date:11/21/2014)... HARROGATE, England , Nov. 21, 2014   TRU-D ... Ltd., will feature their superbug-killing UVC automated disinfection robot, TRU-D ... , this week from Nov. 23 to 26 at Stand ... Societies, is the United Kingdom,s largest ... 15 infection prevention societies to one of the leading events ...
(Date:11/21/2014)... 20, 2014 The California ... research organization representing leading California academic institutions, biotechnology, ... PwC US today released a report revealing ... industry growth. The trend shows a 4 percent ... California Biomedical Industry Report indicates that, while ...
(Date:11/21/2014)... Why did Stephen Hawking become so ... instantly recognizable? Why have they become icons to rival ... Hilton Ratcliffe seeks out the answers to those questions, ... do with science. In " Stephen Hawking Smoked My ... 2014), Ratcliffe puts it plainly: , “It is ...
Breaking Biology Technology:Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4
... 2010 GeNO LLC ( www.genollc.com ), a privately ... the Phase 2 clinical trial for its stand-alone gas ... be studied for nitric oxide delivered via the GeNO ... for administration as an adjunct to right heart catheterization ...
... 2010 / PRNewswire/ -- AltheaDx, Inc. – ... of a strategic partnership with Compendia Bioscience to ... validation and bioinformatics. The two companies will jointly ... biomarker discovery and subsequent development of tests that ...
... Dec. 8, 2010 Shrink Nanotechnologies, Inc. ("Shrink") ... innovative nanotechnology company developing products and licensing opportunities ... sensors and biotechnology research and development tools businesses, ... multi-year development and manufacturing agreement with EV Group, ...
Cached Biology Technology:GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System 2GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System 3AltheaDx and Compendia Bioscience Launch the Breast Cancer Segregation Panel™ 2Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 2Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 3Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 4Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 5
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
(Date:11/18/2014)... 2014   EyeLock Inc. , a market ... MorphoTrust USA (Safran), a leading U.S. provider ... strategic partnership to offer comprehensive biometric identity solutions ... airport screening and financial services markets. ... consumers through a nationwide network of 1,100 IdentoGO® ...
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... the number of bees and other pollinators is not, ... the results of an international study published in the ... Biology . , Co-author, CSIRO Entomology,s Dr Saul ... that demand for pollinators is still growing and some ...
... that plants growing under unfavourable conditions are generally smaller than ... in the US, abiotic stress reduces the yield of agricultural ... the effect of stress in this case, repeated wounding ... which every aspect of their stature, including height, girth, and ...
... CLEVELAND November 10, 2008 A multidisciplinary research team ... Ph.D., a professor in the School of Medicine,s Department ... a number of birth defects that affect the development ... jaw, palate, brain and heart are relatively common congenital ...
Cached Biology News:Pollinator decline not reducing crop yields just yet 2The bonsai effect: Wounded plants make jasmonates, inhibiting cell division, stunting growth 2Case Western Reserve University uncovers genetic basis for some birth defects 2
... designed to speed up the PCR cloning process ... of sequence or type of polymerase used, are ... are difficult to clone by other PCR cloning ... for potentially detrimental proteins can be cloned and ...
Size & Applications: 20 ml Storage Temp.: -20C Shelf Life: 12 months ...
PCR System for increased fidelity, yield and length of PCR products. Amplifies targets up to 10 kb from human genomic DNA....
Immunogen: Heat inactivated bacterial cells of Salmonella enteriditis,paratyphi and typhimurium Storage: 4 C...
Biology Products: